Sanofi, Elan rise on M&A talk

Sanofi-Aventis and Elan saw their stocks leap yesterday on deal rumors: Speculation that Sanofi may buy Merck's interest in its animal-health joint venture Merial sent its shares flying, while rumors that Pfizer might buy Elan boosted the Irish company's stock. Report | Report

Suggested Articles

Amgen could soon face new competition in the PCSK9 class, but an efficacy boost in treating high-risk heart attack patients could help keep it ahead.

In its quest to become the dominant SGLT2 diabetes med for heart failure, Jardiance is touting DPP-4 inhibitor-topping data to support its case.

Despite having lost some of its novelty, AZ's Brilinta is touting bleeding data over aspirin that could be a big break in acute coronary syndrome.